Navigation Links
Computational biochemist uncovers a molecular clue to evolution
Date:9/10/2008

PLoS Biology, a peer-reviewed, open-access journal published by the Public Library of Science. Visit http://biology.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pbio.0060206 to read the paper.

Dan Herschlag, a professor of biochemistry at Stanford University, edited the paper for PLoS Biology. He praised it for its innovative approach.

"This work reveals basic aspects of how enzymes work and how they have evolved," Herschlag said. "The study melds experiment and computation in a powerful fashion and represents a model for how to use interdisciplinary research to answer important questions."


'/>"/>

Contact: Wei Yang
yang@sb.fsu.edu
850-645-6884
Florida State University
Source:Eurekalert  

1

GOOD

Page: 1 2 3

Related biology news :

1. Computational actinide chemistry: Are we there yet?
2. Computational mathematical sciences receives NSF grant for undergraduate research
3. Penn biochemist receives NIH New Innovators Award
4. Biochemists reveal details of mysterious bacterial microcompartments
5. Biochemists manipulate fruit flavor enzymes
6. St. Jude influenza survey uncovers key differences between bird flu and human flu
7. 454 Sequencing uncovers a genetic basis for different social behaviors in wasp
8. Massive microRNA scan uncovers leads to treating muscle degeneration
9. New study uncovers secrets behind butterfly wing patterns
10. UVa Health System team uncovers genes role in type 1 diabetes
11. Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Computational biochemist uncovers a molecular clue to evolution
Computational biochemist uncovers a molecular clue to evolution
Breaking Biology Technology:WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2